The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer: A Randomized Controlled Study
Abstract
BACKGROUND: The use of warfarin sodium for treating venous thromboembolism in patients with cancer is associated with a significant risk of recurrence and bleeding. The use of low-molecular-weight heparin sodium for secondary prevention of venous thromboembolism in cancer patients may reduce the complication rate. OBJECTIVE: To determine whether a fixed dose of subcutaneous low-molecular-weight heparin is superior to oral warfarin for the secondary prophylaxis of venous thromboembolism in patients with cancer and venous thromboembolism. METHODS: In a randomized, open-label multicenter trial performed between April 1995 and March 1999, we compared subcutaneous enoxaparin sodium (1.5 mg/kg once a day) with warfarin given for 3 months in 146 patients with venous thromboembolism and cancer. MAIN OUTCOME MEASURE: A combined outcome event defined as major bleeding or recurrent venous thromboembolism within 3 months. RESULTS: Of the 71 evaluable patients assigned to receive warfarin, 15 (21.1%; 95% confidence interval [CI], 12.3%-32.4%) experienced one major outcome event compared with 7 (10.5%) of the 67 evaluable patients assigned to receive enoxaparin (95% CI, 4.3%-20.3%; P =.09). There were 6 deaths owing to hemorrhage in the warfarin group compared with none in the enoxaparin group. In the warfarin group, 17 patients (22.7%) died (95% CI, 13.8%-33.8%) compared with 8 (11.3%) in the enoxaparin group (95% CI, 5.0%-21.0%; P =.07). No difference was observed regarding the progression of the underlying cancer or cancer-related death. CONCLUSIONS: These results confirm that warfarin is associated with a high bleeding rate in patients with venous thromboembolism and cancer. Prolonged treatment with low-molecular-weight heparin may be as effective as oral anticoagulants and may be safer in these cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Hutten, B. A., Prins, M. H., Gent, M., Ginsberg, J., Tijssen, J. G. P., & Büller, H. R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3078 · Cited by 748
Gould, M. K., Dembitzer, A. D., Doyle, R. L., Hastie, T. J., & Garber, A. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-10-199905180-00003 · Cited by 627
Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous Thromboembolism
Kuijer, P. M. M., Hutten, B. A., Prins, M. H., & Büller, H. R. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.5.457 · Cited by 416
Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism
Schulman, S., & Lindmarker, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422604 · Cited by 326
Gitter, M. J., Jaeger, T. M., Petterson, T. M., Gersh, B. J., & Silverstein, M. D. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.8.725 · Cited by 276
Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread
Hettiarachchi, R., Smorenburg, S., Ginsberg, J., Levine, M., Prins, M., & Büller, H. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615937 · Cited by 206
Major bleeding after hospitalization for deep-venous thrombosis
White, R. H., Beyth, R. J., Zhou, H., & Romano, P. S. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00267-3 · Cited by 198
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
(1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63665-6 · Cited by 171
Bielska-Fałda, H., Noszczyk, W., Bielawiec, M., Witkiewicz, W., Filipecki, S., Michalak, J., Ciesielski, L., Mackiewicz, Z., Częstochowska, E., Zawilska, K., et al. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614412 · Cited by 140
The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer
Bona, R., Sivjee, K. Y., Hickey, A. D., Wallace, D. M., & Wajcs, S. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649881 · Cited by 109
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
Wester, J. P., de Valk, H. W., Nieuwenhuis, H. K., Brouwer, C. B., van der Graaf, Y., Meuwissen, O. J., Hart, H. C., Sixma, J. J., & Banga, J. D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650643 · Cited by 53
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citationAntithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Metadata
- Authors
- Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., & Farge, D.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2002-08-12
- Volume
- 162
- Issue
- 15
- Pages
- 1729
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2070112905
- Cited by
- 796
- References
- 13
- FWCI
- 21.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.